http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106349104-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C249-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C249-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C251-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C251-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-54 |
| filingDate | 2016-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106349104-B |
| titleOfInvention | Oxime and oximido ether compound with anti-hepatitis B activity |
| abstract | The invention discloses oxime and oximido ether compound with anti-hepatitis B activity, structure is below general formulaļ¼ It is confirmed by HepG 2.2.15 cell experiments, oxime of the invention and oximido ether compound all have certain inhibitory action to HBV surface antigen (HBsAg) and e antigens (HBeAg).Under the same terms, positive controls Lamivudine only has HBsAg inhibiting rates 55.51%, and the oxime and oximido ether compound of the present invention can reach HBsAg inhibiting rates 98.67%, and has the characteristics that toxicity is low.The novel oxime and oximido ether compound of the present invention is Nonnucleoside anti-hepatitis B activity compound, is expected to be developed further into the new drug for anti-hepatitis virus. |
| priorityDate | 2016-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.